These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19222741)

  • 1. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the treatment of chronic kidney disease-mineral and bone disorder.
    Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
    J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
    Nguyen TV; Filson J
    Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.
    Román-García P; Carrillo-López N; Cannata-Andía JB
    J Ren Care; 2009 Mar; 35 Suppl 1():34-8. PubMed ID: 19222729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKD-mineral and bone disorder: core curriculum 2011.
    Moorthi RN; Moe SM
    Am J Kidney Dis; 2011 Dec; 58(6):1022-36. PubMed ID: 22018457
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Komaba H; Tanaka M; Fukagawa M
    Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy for ROD and measurement of the bone mass].
    Yamamoto I; Kawamura Y; Hirano K; Hayakawa H; Shigematu T
    Clin Calcium; 2004 Dec; 14(12):83-8. PubMed ID: 15577179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
    Haffner D; Leifheit-Nestler M
    Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mineral and bone disorders in chronic kidney disease.
    Mahon A; Cunningham J
    J Ren Care; 2009 Mar; 35 Suppl 1():2. PubMed ID: 19222723
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study.
    Shaheen FA; Kurpad R; Al-Sayyari AA; Souqiyyeh MZ; Aljubori H; El Baz T; Kashif W; Tuganbekova S; Kabulbayev K; Jarraya F; Nafar M
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. III. Clinical algorithms on renal osteodystrophy.
    Nephrol Dial Transplant; 2000; 15 Suppl 5():39-57. PubMed ID: 11073276
    [No Abstract]   [Full Text] [Related]  

  • 14. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 16. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach.
    Svára F
    J Ren Care; 2009 Mar; 35 Suppl 1():3-6. PubMed ID: 19222724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Estimation of the prevalence of low turn over renal osteodystrophy using biological markers in a peritoneal dialysis population].
    Negri AL; Alvarez Quiroga M; Bravo M; Fradinger E; Jacobo de Marino A; Bogado CE; Zanchetta JR
    Nefrologia; 2001; 21(4):392-4. PubMed ID: 11816516
    [No Abstract]   [Full Text] [Related]  

  • 20. [Physiopathology and therapy of renal osteodystrophy and secondary hyperparathyroidism].
    Fukagawa M
    Nihon Naika Gakkai Zasshi; 1999 Jul; 88(7):1245-50. PubMed ID: 10465972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.